---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-029396"
form_type: "8-K"
ticker: "ENGN"
cik: "0001980845"
company_name: "enGene Therapeutics Inc."
filed_at: "2024-03-11T23:59:59+00:00"
generated_at: "2026-06-05T00:08:51.515653+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# enGene Q1 net loss $10.7M; CEO to resign; $200M PIPE extends cash into 2027

## Summary
- Net loss $10.7M ($0.46/share) vs $8.6M ($13.29/share) YoY; operating expenses $10.8M vs $4.6M.
- Completed $200M oversubscribed PIPE (20M shares at $10, 31% premium); net proceeds $187.5M.
- Cash $85.6M as of Jan 31; with PIPE proceeds, expects runway into 2027.
- CEO Jason Hanson to resign upon appointment of successor; Board conducting search.
- Pivotal Phase 2 LEGEND study for EG-70 in NMIBC on track; interim data mid-2024.

## SEC filing metadata
- accession: 0000950170-24-029396
- form_type: 8-K
- ticker: ENGN
- cik: 0001980845
- company_name: enGene Therapeutics Inc.
- filed_at: 2024-03-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1980845/000095017024029396/0000950170-24-029396-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1980845/000095017024029396/engn-20240311.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-029396
- JSON: https://secwatch.observer/filing/0000950170-24-029396.json
- Plain text: https://secwatch.observer/filing/0000950170-24-029396.txt

## Key facts
- Earnings Releases
  enGene Therapeutics Inc. reported first quarter ended January 31, 2024 results: net income net loss attributable to common shareholders was $10.7 million, or $0.46 per share.
  - Period: first quarter ended January 31, 2024
  - Net income: net loss attributable to common shareholders was $10.7 million, or $0.46 per share
  - Result: reported results
  source text: enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral intravesical lead product candidate, EG-70, is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced its financial results for the first quarter ended January 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1980845/000095017024029396/0000950170-24-029396-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.